General
Preferred name
HYDROXYUREA
Synonyms
hydroxycarbamide ()
nsc32065 ()
nci-c04831 ()
HydroxyureaHydroxycarbamideHydreaHydroxylamine, N-carbamoyl-Hydroxylamine, N-(aminocarbonyl)-N-CarbamoylhydroxylamineN-HydroxyureaHydroxyurea(d4)Carbamoyl oximeHydroxyurea (D4) ()
Hydroxyurea (NSC-32065) ()
NCI-C04831, Hydroxycarbamide,NSC-32065 ()
Hidroxicarbamida ()
NSC-32065 ()
Hydrea ()
SQ-1089 ()
SQ 1089 ()
Droxia ()
Siklos ()
Xromi ()
P&D ID
PD002298
CAS
127-07-1
8029-68-3
Tags
available
drug
Approved by
EMA
FDA
First approval
1967
Drug indication
Chronic myelogenous leukaemia
Leukemia
Drug Status
approved
investigational
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Inhibits ribonucleoside-diphosphate reductase (RR1). (GtoPdb)
TOXICITY Oral, mouse: LD50 = 7330 mg/kg; Oral, rat: LD50 = 5760 mg/kg; Teratogenicity: Teratogenic effects have occurred in experimental animals.Hydroxyurea use during a small number of human pregnancies has been reported. Adverse effects have not been observed in any of the exposed newborns.; Reproductive Effects: Adverse reproductive effects have occurred in experimental animals.; Mutagenicity: Mutagenic effects have occurred in experimental animals.Mutagenic effects have occurred in humans.
DESCRIPTION Hydroxyurea is a cell apoptosis inducer that inhibit DNA synthesis through inhibition of ribonucleotide reductase. Hydroxyurea shows anti-orthopoxvirus activity.
PRICE 29
DESCRIPTION Hydroxyurea is an antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase. Hydroxyurea activates apoptosis and autophagy. (Enamine Bioactive Compounds)
DESCRIPTION Antineoplastic; inactivates ribonucleoside reductase which blocks the synthesis of deoxynucleotides (LOPAC library)
DESCRIPTION Hydroxyurea (Hydroxycarbamide), an antineoplastic agent, inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase. (TargetMol Bioactive Compound Library)
Cell lines
3
Organisms
2
Compound Sets
28
AdooQ Bioactive Compound Library
A10459
Cayman Chemical Bioactives
23725
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
CHEMBL467
ChEMBL Drugs
CHEMBL467
Concise Guide to Pharmacology 2017/18
6822
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DB01005
DrugBank Approved Drugs
DB01005
DrugCentral
1399
DrugCentral Approved Drugs
1399
DrugMAP
DMOQVU9
DrugMAP Approved Drugs
DMOQVU9
DrugMatrix
Enamine Bioactive Compounds
EBC-03024
Enamine BioReference Compounds
Guide to Pharmacology
6822
LOPAC library
MedChem Express Bioactive Compound Library
HY-B0313
NCATS Inxight Approved Drugs
X6Q56QN5QC
NIH Approved Oncology Drugs
90752
NIH Mechanistic Set
Novartis Chemogenetic Library (NIBR MoA Box)
ReFrame library
Selleckchem Bioactive Compound Library
Hydroxyurea(Cytodrox)
TargetMol Bioactive Compound Library
T0676
The Spectrum Collection
External IDs
242
Properties
(calculated by RDKit )
Molecular Weight
76.03
Hydrogen Bond Acceptors
2
Hydrogen Bond Donors
3
Rotatable Bonds
0
Ring Count
0
Aromatic Ring Count
0
cLogP
-0.96
TPSA
75.35
Fraction CSP3
0.0
Chiral centers
0.0
Largest ring
0.0
QED
0.26
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Selectivity
Ribonucleoside reductase
MOA
ribonucleoside-diphosphate reductase inhibitor
Nitric oxide donor
Ribonucleoside-Diphosphate Reductase Inhibitors
Antimetabolites
Ribonucleotide Reductase inhibitor
Target
Ribonucleoside-diphosphate reductase RR1
RRM1, RRM2, RRM2B
Apoptosis related,Autophagy,DNA/RNA Synthesis,HIV
DNA/RNA Synthesis
HIV
Orthopoxvirus
ribonucleoside diphosphate reductase
Member status
virtual
Indication
chronic myeloid leukemia (CML), head and neck squamous cell carcinoma (HNSCC)
Disease Area
hematologic malignancy, oncology
Pathway
Apoptosis
Autophagy
Cell Cycle/Checkpoint
DNA Damage/DNA Repair
Microbiology/virology
Proteases/Proteasome
Anti-infection
Cell Cycle/DNA Damage
Therapeutic Class
Anticancer Agents
Source data